Actinogen Medical (ASX: ACW) has now enrolled 60 participants in its phase 2b/3 XanaMIA trial of Xanamem, its treatment candidate for Alzheimer's disease, and expects to reach 100 by the end of the quarter, triggering an interim data analysis, according to a Wednesday statement by the company.
The trial targets Alzheimer's disease patients with elevated pTau181 levels, a biomarker linked to disease progression, to better detect Xanamem's treatment benefit.
Final results for the full 220 participants are expected in the fourth quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.